SAGA DIAGNOSTICS
LIVE

Serial Number

79296383

Owner

SAGA Diagnostics AB

Attorney

Sarah J. Schneider

Filing Date

Mar 5, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SAGA DIAGNOSTICS Trademark

Serial Number: 79296383 • Registration: 6504579

SAGA DIAGNOSTICS is a trademark filed by SAGA Diagnostics AB on March 5, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

SAGA Diagnostics AB (6 trademarks)

Medicon Village,

Entity Type: 03

Trademark Details

Filing Date

March 5, 2020

Registration Date

October 5, 2021

Published for Opposition

July 20, 2021

Goods & Services

Biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; chemical preparations for use in DNA analysis for medical purposes; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the prevention of tumours; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; nucleic acid sequences for medical and veterinary purposes; medical diagnostic reagents and assays for testing of body fluids; clinical medical reagents; veterinary diagnostic reagents; medical diagnostic reagents; reagents for medical use; chemical reagents for veterinary use; chemical reagents for medical use; reagents for microbiological analysis for veterinary use; reagents for microbiological analysis for medical use; diagnostic reagents for medical use; diagnostic reagents for medicinal use; immunoassay reagents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; chemical diagnostic reagents for medical use; reagents for analytical purposes for medical purposes; reagents for blood grouping for medical purposes; reagents for microbiological analysis for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in diagnostic pregnancy tests; chemical reagents for medical or veterinary purposes; reagents for use in analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for in-vitro laboratory use for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for in-vitro laboratory use for veterinary purposes; genetic identity tests comprised of reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in veterinary genetic testing; genetic identity tests comprised of reagents for medical purposes

Lung cancer screening services; prostate cancer screening services; breast cancer screening services; bowel cancer screening services; cervical cancer screening services; providing cancer screening services; testicular cancer screening services; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical services for the treatment of skin cancer; RNA or DNA analysis for cancer diagnosis and prognosis provided by medical laboratories; genetic testing of animals for diagnostic or treatment purposes; medical testing for diagnostic or treatment purposes; DNA screening for medical purposes; drug, alcohol and DNA screening for medical purposes; RNA or DNA analysis for cancer diagnosis and prognosis; medical and health services relating to DNA, genetics and genetic testing; genetic counseling; genetic testing of animals for diagnostic or treatment purposes; genetic testing for medical purposes; genetic testing of animals for diagnostic or treatment purposes

Scientific research for medical purposes in the area of cancerous diseases; scientific laboratory services, laboratory research services relating to detection of sequence variants in DNA or RNA; laboratory testing services relating to detection of sequence variants in DNA or RNA; analytical medical laboratory services; analytical veterinary laboratory services; scientific laboratory services; medical laboratory services; veterinary laboratory services; medical chemical laboratory services; medical biological laboratory services; medical research laboratory services; medical chemical research laboratory services; medical biological research laboratory services; medical laboratory services for analytical testing; medical services of a chemical laboratory; DNA testing services to determine paternity laboratory services; laboratory research services relating to dermatology; laboratory research services relating to pharmaceuticals; medical services of a chemical and/or biological laboratory; medical laboratory services relating to the production of monoclonal antibodies; DNA screening for scientific research purposes; clinical trials for others; conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; conducting clinical trials in the field of cardiovascular disease for others; conducting clinical trials in the field of acupuncture therapy for others; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical research in the field of cancer and infectious diseases; biological research, clinical research and medical research; basic and clinical research in the field of respiratory science and medicine; pharmaceutical research services; research on the subject of pharmaceuticals; pharmaceutical research and development; research relating to pharmaceuticals; pharmaceutical research and development services; laboratory research services relating to pharmaceuticals; research on the subject of pharmaceuticals; consultancy relating to pharmaceutical research and development; research and development for the pharmaceutical industry; consultancy in the field of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; scientific research, namely, genetic engineering services; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; genetic testing for scientific research purposes; scientific research, namely, genetic engineering services relating to plants; medical research in the field of gene therapy; scientific research relating to genetics of plants; laboratory research in the field of gene expression; genetic testing of laboratory animals for research purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jul 24, 2023 NREP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 15, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 15, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 15, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 15, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 15, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 15, 2022 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 18, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 24, 2022 FICS
FINAL DISPOSITION PROCESSED
Mar 24, 2022 FIMP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 21, 2022 NREP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 5, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 5, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 20, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 20, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Jul 19, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 30, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 30, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 30, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 14, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 14, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 14, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 14, 2021 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 1, 2021 GNFN
FINAL REFUSAL E-MAILED
Jun 1, 2021 GNFR
FINAL REFUSAL WRITTEN
Jun 1, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 30, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 30, 2021 TROA
REFUSAL PROCESSED BY IB
Jan 4, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 11, 2020 RFCS
REFUSAL PROCESSED BY MPU
Dec 11, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 26, 2020 RFCR
NON-FINAL ACTION WRITTEN
Nov 25, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 24, 2020 MAFR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 19, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 19, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 19, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 19, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 19, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 19, 2020 COAR
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 18, 2020 LIMI
ASSIGNED TO EXAMINER
Nov 18, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2020 NWOS
NEW REPRESENTATIVE AT IB RECEIVED
Nov 13, 2020 NREP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 22, 2020 REPR